These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31665735)

  • 1. Comparison of Six Different Allergen Extracts for Subcutaneous Specific Immunotherapy in Children: An Open-Labelled, Prospective, Controlled Observational Trial.
    Kopp MV; König IR; Friedrichs F; Umpfenbach HU; Niggemann B; Millner-Uhlemann M
    Int Arch Allergy Immunol; 2019; 180(4):284-290. PubMed ID: 31665735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
    Dranitsaris G; Ellis AK
    J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety.
    Creticos PS; Pfaar O
    Immunotherapy; 2018 Jun; 10(7):605-616. PubMed ID: 29634392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland.
    Brüggenjürgen B; Reinhold T
    J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
    Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
    Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review.
    Kim JM; Lin SY; Suarez-Cuervo C; Chelladurai Y; Ramanathan M; Segal JB; Erekosima N
    Pediatrics; 2013 Jun; 131(6):1155-67. PubMed ID: 23650298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
    McCormack PL; Wagstaff AJ
    Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual immunotherapy: allergen specific or placebo effect?
    Kette F; Smith W
    J Allergy Clin Immunol; 2011 Aug; 128(2):430; author reply 430-2. PubMed ID: 21665261
    [No Abstract]   [Full Text] [Related]  

  • 13. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy.
    Nelson H; Cartier S; Allen-Ramey F; Lawton S; Calderon MA
    J Allergy Clin Immunol Pract; 2015; 3(2):256-266.e3. PubMed ID: 25609326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.
    Pokladnikova J; Krcmova I; Vlcek J
    Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.
    Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L
    Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
    Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
    Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization.
    Vourdas D; Syrigou E; Potamianou P; Carat F; Batard T; André C; Papageorgiou PS
    Allergy; 1998 Jul; 53(7):662-72. PubMed ID: 9700035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study.
    Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML; Bruno ME; Falagiani P; Riva G
    Allergol Immunopathol (Madr); 2006; 34(5):194-8. PubMed ID: 17064648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.